Abiraterone Acetate Tablets (I)

Abiraterone Acetate Tablets (I) is a generic formulation of abiraterone acetate developed by Jiangsu HengRui Medicine Co., Ltd. for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a small molecule prodrug that, upon oral administration, is converted to the active form, abiraterone. Abiraterone acts as a potent and selective inhibitor of the enzyme CYP17 (17α-hydroxylase/C17,20-lyase), which is essential for androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissues. By blocking this enzyme, the drug significantly reduces serum testosterone levels, which is a primary driver of prostate cancer progression. In clinical development, this formulation is being compared to the reference branded product, ZYTIGA, to demonstrate bioequivalence and comparable efficacy in suppressing testosterone in patients with mCRPC. It is typically administered in combination with prednisone to manage potential mineralocorticoid-related side effects resulting from CYP17 inhibition.

Brand names

Zytiga

Other names

abiraterone acetateHengRui abiraterone acetate